Last $20.64 USD
Change Today +0.25 / 1.23%
Volume 1.1M
ISIS On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 4:30 PM 05/23/13 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

B. Lynne Parshall Esq., J.D.

Chief Operating Officer, Secretary and Director, Isis Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 50 board members in 4 different organizations across 5 different industries.

See Board Relationships
56$1,171,615
As of Fiscal Year 2012

Background*

Ms. B. Lynne Parshall, Esq., J.D. has been the Chief Operating Officer of Isis Pharmaceuticals, Inc. since December 2007 and also serves as its Secretary. Ms. Parshall served as Chief Financial Officer since June 1994 and also serves as its Principal Accounting Officer and Secretary. Ms. Parshall is responsible for overseeing the operations of finance, legal, patents, manufacturing and business development and is also involved in Isis Pharmaceuticals, Inc.’s corporate ...

Read Full Background

Corporate Headquarters*

2855 Gazelle Court
Carlsbad, California 92010

United States

Phone: 760-931-9200
Fax: --

Board Members Memberships*

Board Member
Former Director
2000-Present
Chief Operating Officer, Secretary and Director
2005-Present
Director, Chairman of Audit Committee and Member of Nominating & Governance Committee
2005-N/A
Former Director and Chairman of Audit Committee
2009-Present
Director and Chairman of Audit Committee
2013-Present
Director and Member of Audit Committee

Education*

BA
Harvard University
JD
Stanford University Law school

Other Affiliations*

Annual Compensation*

Salary$641,574
Bonus$256,630
Total Annual Compensation$898,204

Stock Options*

Restricted Stock Awards$52,136
All Other Compensation$22,600
Exercised Options74,506
Exercised Options Value$688,769
Exercisable Options425,238
Exercisable Options Value$240,030
Unexercisable Options118,552
Unexercisable Options Value$202,673
Total Value of Options$1,131,473
Total Number of Options618,296

Total Compensation*

Total Annual Cash Compensation$920,804
Total Short Term Compensation$898,204
Other Long Term Compensation$74,736
Total Calculated Compensation$1,171,615
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISIS:US $20.64 USD +0.25

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
George W. Hebard III, M.B.AInterim Principal Executive Officer, Interim Chief Operating Officer and Director
Enzon Pharmaceuticals Inc.
$226.4K
Christopher Nishan Garabedian Chief Executive Officer, President and Director
Sarepta Therapeutics, Inc.
$490.0K
John M. Maraganore Ph.D.Chief Executive Officer and Executive Director
Alnylam Pharmaceuticals, Inc.
$669.5K
Kleanthis G. Xanthopoulos Ph.D.Chief Executive Officer, President and Director
Regulus Therapeutics Inc.
$515.5K
Compensation as of Fiscal Year 2012.

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ISIS PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.